DGX
Quest Diagnostics, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$247.06
−1.50%Year over year
Reported trailing growth
- Revenue
- +9.1%
- EBITDA
- +7.7%
- EBIT
- +12.9%
- EPS
- +17.8%
- Free cash flow
- -1.3%
- Operating cash flow
- +3.5%
Forward estimates
Based on analyst estimates
- Revenue
- +5.5%
- EBITDA
- +12.7%
- EPS
- +14.0%
Three-year CAGR
- Revenue
- +3.7%
- EBITDA
- +6.4%
- EBIT
- +3.9%
- Net income
- +1.6%
- EPS
- +3.0%
- Free cash flow
- +1.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026